Oxford-based Circassia reports revenue growth of 27%
The medical device company focused on point of care asthma diagnosis and management released a trading update for the six months ended 30 June 2021.
Circassia Pharmaceuticals to transfer respiratory medicine rights AstraZeneca
Circassia Pharmaceuticals has announced it intends to terminate its U.S. commercial rights to Tudorza® and Duaklir® and transfer the assets to AstraZeneca.
CIP Merchant Capital announces investment in Oxford-based Circassia
CIP Merchant Capital has announced its investment in Oxford-based Circassia, acquiring 12.8m ordinary shares, representing 3.4% of issued share capital, for £2.8m.
Circassia announces business update for 31 December 2019
Oxford-based Circassia Pharmaceuticals has announced a business update including a trading update for the year ended 31 December 2019.
